Alimera Sciences Inc.
NASDAQ:ALIM 4:00:00 PM EDT
| Market Cap (Intraday) | 20.38M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | 8.38 |
| 10-Day MA | $2.55 |
| 50-Day MA | $2.06 |
| 200-Day MA | $3.50 |
Alimera Sciences Inc. Stock, NASDAQ:ALIM
6310 Town Square, Suite 400, Alpharetta, Georgia 30005
United States of America
Phone: +1.678.990.5740
Number of Employees: 158
Description
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.